Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial.

Autor: Kettana KM; Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. khlood.kettana@pharm.tanta.edu.eg., El-Haggar SM; Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt., Alm El-Din MA; Clinical Oncology Department, Faculty of Medicine, Tanta University, Tanta, Egypt., El-Afify DR; Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Jazyk: angličtina
Zdroj: Medical oncology (Northwood, London, England) [Med Oncol] 2024 Jul 08; Vol. 41 (8), pp. 196. Date of Electronic Publication: 2024 Jul 08.
DOI: 10.1007/s12032-024-02426-1
Abstrakt: Cardiotoxicity is a side effect of chemotherapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients receiving both anthracyclines and trastuzumab. We looked for a possible protective effect of rosuvastatin against chemotherapy-induced cardiotoxicity. Methods: 50 newly diagnosed HER2 positive breast cancer patients were randomly allocated into two groups: 25patients in each. Group 1(control group) received doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy. Group 2 (treatment group) received doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy and 20 mg of oral rosuvastatin 24 h before the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months). Transthoracic echocardiography was done, and blood samples were collected for patients 24 h before the initiation of therapy, after 3 months and after 6 months to assess serum levels of high sensitivity cardiac troponin I (hs-cTnI), Myeloperoxidase (MPO), Interleukin-6 (IL-6) and Alanine aminotransferase (ALT). The study was retrospectively registered in Clinical Trials.gov in April 2022. Its ID is NCT05338723. Compared to control group, Rosuvastatin-treated group had a significantly lower decline in LVEF after 3 months and after 6 months. They had significantly lower Hs-cTnI and IL-6 after 3 months and after 6 months, and significantly lower MPO after 6 months. Four patients in control group experienced cardiotoxicity while no one in rosuvastatin-treated group. Rosuvastatin attenuated cardiotoxicity, so it is a promising protective agent against chemotherapy-induced cardiotoxicity.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: